Background: The zinc finger protein A20 is an ubiquitinating/deubiquitinating enzyme essential for the termination of inflammatory reactions through the inhibition of nuclear factor kappaB (NF-kappaB) signaling. Moreover, it also shows anti-apoptotic activities in some cell types and proapoptotic/pronecrotic effects in others. Although it is known that the regulation of inflammatory and cell death processes are critical in proper brain functioning and that A20 mRNA is expressed in the CNS, its role in the brain under physiological and pathological conditions is still unknown. Methods: In the present study, we have evaluated the effects of A20 overexpression in mixed cortical cultures in basal conditions: the in vivo pattern of endogenous A20 expression in the control and N-methyl-D-aspartate (NMDA) excitotoxically damaged postnatal day 9 immature rat brain, and the post-injury effects of A20 overexpression in the same lesion model. Results: Our results show that overexpression of A20 in mixed cortical cultures induced significant neuronal death by decreasing neuronal cell counts by 45¡9%. In vivo analysis of endogenous A20 expression showed widespread expression in gray matter, mainly in neuronal cells. However, after NMDA-induced excitotoxicity, neuronal A20 was downregulated in the neurodegenerating cortex and striatum at 10-24 hours post-lesion, and it was re-expressed at longer survival times in reactive astrocytes located mainly in the lesion border. When A20 was overexpressed in vivo 2 hours after the excitotoxic damage, the lesion volume at 3 days post-lesion showed a significant increase (20.8¡7.0%). No A20-induced changes were observed in the astroglial response to injury. Conclusions: A20 is found in neuronal cells in normal conditions and is also expressed in astrocytes after brain damage, and its overexpression is neurotoxic for cortical neurons in basal mixed neuron-glia culture conditions and exacerbates postnatal brain excitotoxic damage.
Background
In the nervous system, nuclear factor kappaB (NFkappaB) is involved in regulating responses of neurons and glial cells to activation, acting on several signalling pathways and in a variety of physiological and pathological situations. 1 In neuronal cells, NFkappaB mediates cell survival and plasticity, and in glial cells, it contributes to the coordination of the inflammatory response upon damage or infection. 2, 3 The zinc finger protein A20 is a complex molecule essential for the termination of inflammatory reactions by its inhibitory properties on NF-kappaB signalling [4] [5] [6] based on its ubiquitinating/deubiquitinating activity. [7] [8] [9] Ubiquitination of proteins by the covalent ligation of one or several monomers of the ubiquitin protein is a major regulatory mechanism for a wide array of cellular processes, including endocytosis, vesicle trafficking, cell-cycle control, stress response, DNA repair, cell signalling, and gene transcription and silencing. 10 Interestingly, A20 is capable of removing polyubiquitin chains from a specific lysine of critical factors of the NF-kappaB signalling cascade-like TRAF6 and RIP1, but it can also polyubiquitinate RIP1 on another lysine, thereby inhibiting tumor necrosis factor-alpha receptors (TNF-alphaR) and Toll-like receptors activation of NF-kappaB. 5, 7, 8 Accordingly, A20 knockout mice develop severe inflammation and cachexia, are hypersensitive to inflammatory stimuli such as bacterial lipopolysaccharide and TNF-alpha treatment, and die prematurely. 4 Moreover, A20 has also been shown to participate in the regulation of cell death in a variety of cell types, showing anti-apoptotic activity in some cell types but pro-apoptotic/pro-necrotic effects in others.
As an example, A20 protects pancreatic beta cells 11, 12 and other cell types 4, 13 from TNF-alpha, interleukin1beta or interferon-gamma induced apoptosis. However, while protecting against TNF-alpha-induced apoptosis, A20 also sensitizes these cells to necrosis triggered by reactive oxygen species 14 and sensitizes smooth muscle cells to cytokine and Fas-induced apoptosis by a nitric oxide dependent mechanism. 15 Similarly, in a model of induced cell death in T lymphocyte hybridomas, A20 may promote pro or anti-apoptotic effects depending on the stimulus. 16 Noteworthy, although it is known that A20 mRNA is expressed in the central nervous system (CNS), 17 and that it has been long established that NF-kappaB plays a key role in neuronal fate, no studies have analyzed the A20 protein cellular expression pattern in the CNS or the role of A20 in cell survival or death of CNS cells. In this sense, one aim of this study was to evaluate the effects of A20 overexpression on the survival of neuronal cells under basal conditions in vitro and to describe the in vivo brain expression of A20 in the control brain. Moreover, brain damage as a result of perinatal hypoxic-ischemic insult is a serious clinical problem with severe neurological consequences, where inflammation is known to play a fundamental role. 18, 19 In fact, several lines of evidence suggest that the immature brain responds in a particular fashion to brain injuries, 18, 19 at least in part due to the fact that many of the adult gene expression patterns, neural circuits organization, cell differentiation, or myelination have not yet been achieved. 20, 21 For instance, the postnatal brain is more sensitive than the adult brain to the neurotoxic actions of N-methyl-D-aspartate (NMDA). 22 Thus, in this work, we also aimed to analyze the expression of A20 after a postnatal NMDA-induced excitotoxic injury and, finally, the effects of A20 overexpression after the mentioned excitotoxic postnatal injury using a previously described gene delivery approach.
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Methods
In vitro studies
Cell cultures and transfection Primary cortical cultures were prepared from E17 Oncins France Strain A rat embryos by dissecting the cerebral cortices free of meninges. After dissociation, cells were plated at a density of 1.8610 6 cells/ml in BME medium (04-25050; Pan Biotech) supplemented with 5% foetal horse serum (FHS; Invitrogen), 5% foetal calf serum (FCS; Invitrogen), glutamine 2mM, 0.6% glucose, 50 U/ml penicillin, and 50 mg/ml streptomycin on 10 mg/ml polylysine coated wells. At 7 days in vitro, mixed neuron-glia cultures were prepared by removing the medium with FCS and adding a total of 10% FHS and 10 mM cytosine arabinoside in the same medium. Under these conditions and as described earlier, 27 at 10-12 days in vitro, when mixed neuron-glia cultures were used, these contained an average of 21¡2% glial fibrillary acidic protein (GFAP)-positive astrocytes and 11¡2% NDPase-positive microglial cells. In vitro transfection of these cultures was performed by washing once in OPTIMEM medium, and incubating for 5 hours in 4.5-6 mg lipofectamine (Invitrogen) and 1 mg DNA per 24-well plate well, followed by the addition of BME supplemented with 10% FHS or DMEM supplemented with 10% FCS respectively as described elsewhere. Control cultures were incubated with lipofectamine alone in the same conditions. The recombinant transfection vehicle NLSCt, used in this study for in vivo delivery and overexpression of A20 gene, cannot be used in vitro under basal conditions as its mediated transfection efficiency is too low.
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The plasmids used for transgene overexpression were: (1) a negative control transgene, the red-shifted variant of jellyfish Aequorea Victoria green fluorescent protein (GFP) gene encoded into plasmid pEGFP-C1 (Clontech) under control of CMV promoter and SV40 enhancer element; and (2) the A20 transgene encoded into plasmid pCAGGS under the control of the chicken beta-actin/rabbit beta-globin hybrid promoter. 28 
Cell viability
Mixed neuron-glia cortical cultures were evaluated for overall cell viability using the spectrophotometric 3-[4,5-dimethylthiazol-2-yl]-2,5-dephenyl tetrazolium bromide (MTT) assay by incubating cultures for 45 minutes at 37uC with 5% CO 2 and 0.2 mg/ml MTT. Cells were then lysed in DMSO and the amount of MTT product (coloured formazan) was determined by measuring absorbance at 570nm and at 630nm. Neuronal cell viability was evaluated by immunocytochemical labelling using a mouse monoclonal primary antibody anti-microtubule-associated protein 2 (MAP2, 1 : 1500, MAB 3418; Chemicon) and anti-mouse HRP-linked (1 : 200, NA931V; Amersham Bioscience) as secondary antibody. Visualization of immunostaining was performed using 3,39-diaminobenzidine (DAB)-hydrogen peroxide as the developing procedure. Immunoreactive cells were counted in eight 640 fields in each well. All experiments were performed at least three times in triplicate.
In vivo studies
Experimental animals Experimental animal work was conducted according to Spanish regulations in agreement with European Union directives. Experimental procedures were approved by the ethical commission of the Autonomous University of Barcelona. A total of 34 Long-Evans black-hooded postnatal day 9 rats, distributed in several experimental groups, were used in this study.
Excitotoxic injury
Nine-day-old Long-Evans black-hooded rat pups (15-20 g, both sexes; Janvier, France) were used. Intracerebral injections were made into the right sensorimotor cortex at the level of the coronal suture (2 mm lateral of bregma and 0.5 mm depth) using a stereotaxic frame adapted for newborns (Kopf Instruments) under isoflurane (Baxter International Inc.) anesthesia. Excitotoxic lesions were performed as previously described, 29 by injecting 18.5 nmol of NMDA (Sigma-Aldrich, St Louis, MO, USA) diluted in 0.15 ml of saline solution (0.9% NaCl) (n59) or the saline solution alone (vehicle controls) (n56) at a rate of 0.05 ml/min using an automatic injector. The needle was left in place for 10 additional minutes to allow diffusion. After suture, pups were placed on a thermal pad for 2 hours at 36uC to maintain normothermia.
Endogenous A20 analysis by immunohistochemistry At 10, 24, or 72 hours post-lesion, two salineinjected controls and three NMDA-injected brains for each survival time, together with intact-postnatal day 9 pups (n53) were anesthetized and perfused intracardially with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Brains were post-fixed in the same fixative for 2 hours and crioprotected overnight in a 30% sucrose solution before being frozen with dry CO 2 . Coronal sections of the entire brain (30 mm thick) were obtained using a Leitz cryostat. Sections were processed for endogenous peroxidase inactivation by 10 minutes. incubation in 70% methanolz2%H 2 O 2 , and then blocked for 1 hour in Tris-buffered saline (pH 7.4) plus 10% FCS and 1% Triton X-100. Sections were then incubated overnight at 4uC and 1 hour at room temperature in the same blocking solution containing a chicken polyclonal primary antibody anti-A20 (1 : 300, Genway biotech 15-288-21173). After several washes, sections were incubated for 1 hour at room temperature with a secondary biotinylated anti-chicken antibody (1 : 300, Genway biotech) and, subsequently with avidin-HRP (Dakopatts, PO364). Finally, DAB-hydrogen peroxide was used as developing procedure for immunolabelling visualization. Control sections were processed similarly, but omitting the primary antibody.
Transgene overexpression after excitotoxicity and sample processing The effects exerted by A20 overexpression after excitotoxic damage was analyzed in another set of animals. For this in vivo gene therapy study, a previously generated recombinant gene delivery vehicle termed NLSCt was used (1 ml, 7 mM). 23 NLSCt protein and DNA complexes were formed by incubation of NLSCt and the plasmids detailed above for the in vitro experiment in 0.9% NaCl at room temperature for 1 hour at ratios of 0.03 mg DNA per mg of NLSCt protein, thereby obtaining NLSCt/ EGFP or NLSCt/A20 complexes. Sixteen rat pups from 3 l were excitotoxically lesioned as described above and, 2 hours later, re-injected at 0.2 ml/min at the same coordinates, as previously described in detail, 25, 26 with either NLSCt/EGFP (n58) or NLSCt/A20 (n58). Both treatments were made in each litter. At 3 days post-lesion, animals transfected with the different transgenes were anesthetized and perfused intracardially with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) and processed for cryostat sectioning as described before in the immunohistochemistry section.
Lesion volume measurement
One series of slide-mounted sections (separated by 240 mm) per animal were stained for Nissl and used for the measurement of lesion volume and total ipsilateral hemisphere volume after high-resolution digitalization with a Nikon LS-1000 slide scanner. Using analySIS software tools and simultaneous microscope observation, the lesioned area, identified by its pale Nissl staining and unstructured citoarchitecture, was quantified in each section. To avoid miss-interpretations related to possible tissue edema or shrinkage, data are presented as the percentage of total ipsilateral hemisphere volume.
Analysis of astroglial response
For astroglial cell labelling, another series of parallel free-floating sections per animal were processed for endogenous peroxidase inactivation and blocked for 1 hour in Tris-buffered saline (pH 7.4) plus 10% FCS and 1% Triton X-100. Sections were then incubated overnight at 4uC plus 1 hour at room temperature in the same blocking solution containing a rabbit polyclonal primary antibody against GFAP (1 : 1000, Z-0334; Dakopatts, Glostrup, Denmark). After several washes, sections were incubated for 1 hour with horseradish-linked anti-rabbit secondary antibody (1 : 200, NA934V; Amersham Biosciences, Piscataway, NJ, USA), and DAB-hydrogen peroxide was used as developing procedure for immunolabeling visualization. Control staining omitting the primary antibody was performed in order to analyze potential unspecific immunolabeling.
For densitometrical analysis of astroglial GFAP expression, three consecutive 620 images of each animal taken at the lesion core and at the lesion border conformed the region of interest (ROI) and were analyzed by using analySIS software tools. As previously described, 26, 30 the mean gray value of ROI, and the area occupied by immunoreactive cells within ROI were obtained for each image, representing the total immunostaining intensity and the area of ROI occupied by immunoreactive cells respectively.
Data processing and statistical analysis
All results are expressed as mean¡standard error mean. Student's t-test was used to determine significant differences (P,0.05). In vitro experiments were performed al least three times in triplicates.
Results

In vitro overexpression of A20
In order to evaluate the effects of A20 overexpression in basal conditions, cortical mixed neuron-glia cultures were transfected with A20 or GFP transgenes by means of the widely used lipofectaminemediated transfection method. Seventy-two hours after culture transfection and when compared to lipofectamine alone and GFP-transfected controls, overexpression of A20 in cortical cultures induced several effects, namely, significant cell death, as observed by phase contrast microscopy (Fig. 1A) ; a significant reduction in cell viability, as demonstrated by decreased levels in MTT reduction (46¡4% reduction as compared to gene therapy control GFP-transfected cultures , Fig. 1B) ; a decrease in MAP2 z neuronal cell number (45¡9% reduction when compared to GFP-transfected cultures, Fig. 1A and C), and increased propidium iodide staining (data not shown).
In vivo spatio-temporal expression pattern of A20 in the control and excitotoxically-damaged postnatal rat brain
The non-lesioned immature brain showed widespread A20 staining, mainly in gray matter areas (Fig. 2) . A20 staining appeared as a cytoplasmic fine punctuate in neuronal cells, mainly located in the neocortex, hippocampus, anterodorsal thalamus, septum and indusium griseum, caudate putamen, globus pallidus, pyriform cortex, and olfactory bulb. More specifically, in the striatum, weak immunoreactivity was observed between the fiber bundles, where few faintly stained neurons were seen ( Fig. 2A) . In the neocortex, the highest expression of A20 was seen in layer V pyramidal neurons, although staining was also observed in layers I, II, and III (Fig. 2B) . Moreover, subplate neurons of the neonatal neocortex were also stained (Fig. 2B) . Regarding the hippocampus, A20 was mainly observed in the CA2 region, but also in CA1 and the dentate gyrus, whereas CA3 showed very faint staining (Fig. 2C) . The olfactory bulb showed intensely stained neurons in several layers (Fig. 2D) . Finally, the ventricular walls also showed punctuate A20 staining, as did the choroid plexus. Saline-injected control animals showed, at 10 hours post-injection, an identical pattern as non-injected animals, except for a slight bilateral increase in A20 immunoreactivity in some neurons of the septum (Fig. 3A and B) . Both at 24 and 72 hours postinjection, a very restricted and slight upregulation of A20 was also noted in cortical neurons at the level of the injection (Fig. 3C) .
NMDA injection into the sensorimotor cortex of the immature postnatal day 9 rat brain induced a previously characterized excitotoxic lesion that included a primary lesion involving the sensorimotor cortex and secondary lesioned areas like the caudal sub-plate neuronal layer, striatum, and hippocampus, as previously described in detail. 29, 31 Excitotoxically lesioned animals showed an increase in A20 immunoreactivity in the septum, similar to saline-injected animals, but in addition, they exhibited a decrease in neuronal A20 immunoreactivity within the neocortical lesion core at 10 hours post-lesion (cf. Fig. 3D and E). After 24 hours, neuronal decrease in A20 was seen throughout the lesioned neocortex and dorsal striatum (cf. Fig. 3G and H) , but not in the lesioned hippocampus. At 72 hours post-lesion, decreased neuronal immunoreactivity for A20 was still observed in the cortical lesion core, which was now surrounded by A20 z reactive astroglial-like cells in the lesion periphery of the cortex (cf. Fig. 3J and K), striatum and hippocampus (cf. Fig. 3I and L) . Interestingly, A20 labeling in astroglial-like cells was more intense in the hippocampus than in the other neurodegenerating areas such as the cortex, not only in regard to the intensity of immunoreactivity, but also in the amount of A20 z astroglial-like cells (cf. Fig. 3K and L). Finally, round cells resembling mast cells or macrophages showing intense intracellular A20 z granular structures were observed in the fimbria (Fig. 3F) .
In vivo overexpression of A20 after an excitotoxic lesion to the immature rat brain of lesioned hemisphere in relation to the gene therapy control group NLSCt/GFP) (Fig. 4) . Moreover, as A20 was observed in reactive astrocytes after the lesion, we evaluated the effects of experimentally induced A20 overexpression on the astroglial response by GFAP immunoreactivity. At 72 hours after the lesion, in the gene therapy control GFP-transfected group, GFAP z astroglial cells showed a reactive morphology with strong GFAP expression and thick processes, as we have previously Figure 3 A20 expression in the excitotoxically injured immature brain. Control animals injected intracortically with saline showed, 10 hours after the injection, slight bilateral upregulation of A20 in some neurons of the septum (A, B), and 24 hours after the saline injection, restricted upregulation of A20 was noted in cortical neurons of the injection point (C, asterisk: injection point). In contrast, NMDA injection induced a decrease in neuronal A20 immunoreactivity in the neocortical injection point at 10 hours (E) when compared to control (not shown) or saline injected neocortex (D). After 24 hours, neuronal decrease in A20 was also seen in the dorsal caudate putamen (CP) and globus pallidus (GP) (H, arrows) when compared to striatum of saline injected animals (G). Seventy-two hours after the lesion, A20-positive reactive astrocytes were observed in the cortical lesion periphery (K, asterisk: lesion core) and in the entire hippocampus (L), as compared to neuronal labelling in the neocortex (J) and hippocampus (I) of saline-injected animals. Rounded cells with irregular limits and very intense intracellular A20 positive granular structures were observed at the fimbria (F). Scale bars: A, C, G, and H: 200 mm; E and D: 100 mm; B, F, J, K, I, and L: 20 mm.
described in the excitotoxically lesioned postnatal brain. 32 Similar distribution and astroglial morphology was observed after A20 overexpression (Fig. 5A) .
In this sense, quantitative densitometrical analysis of GFAP immunoreactivity (Fig. 5B) or analysis of the total area within ROI occupied by GFAP z astrocytes ( Fig. 5C ) confirmed that there were no significant differences in the astroglial response after A20 overexpression when compared to the control group transfected with GFP.
Discussion
The present study shows for the first time that the NF-kappaB binding molecule A20 is widely expressed on CNS neuronal cells under physiological conditions. After acute excitotoxic damage in the immature brain, neuronal A20 is rapidly downregulated in the lesion core, followed by a later upregulation in astrocytes. In addition, A20 overexpression, either in vitro under basal conditions or in vivo after the acute excitotoxic damage, induces an increase in neuronal cell death, contributing to the hypothesis that A20 plays a pivotal role in determining cell death/survival also in the CNS.
Expression of endogenous A20
A20 is a NF-kappaB binding molecule that was first described as an inhibitor of NF-kappaB signalling after activation of this transcription factor by inflammatory mediators acting on TNF-alphaR), interleukin-1beta receptors, and Toll-like receptors. [7] [8] [9] In addition, A20 is a NF-kappaB-regulated gene itself and therefore, its expression has been shown to be NFkappaB-dependent. 33 In this regard, the previously reported presence of constitutive NF-kappaB activity in the CNS under physiological conditions [34] [35] [36] could account for the constitutive expression of A20 in the control brain described here. By using kappaB reporter mice, Bhakar and co-workers nicely described constitutive NF-kappaB activity mainly in neurons, particularly in the neocortex, pyriform cortex, hippocampus, amygdala, olfactory bulb, and olfactory tubercle (Islands of Calleja). 37 Accordingly, we here show that the immature rat brain showed widespread A20 expression in the gray matter, mainly in neuronal cells, with particularly high expression in mostly the same areas where constitutive NF-kappaB has been shown. Some differences exist, however, between the two expression patterns, which can easily be explained by variations on the kB binding sites used in the kappaB reporter mice and the one of the A20 gene. In fact, it is interesting to note that there is considerable diversity in the DNA binding properties of the different NFkappaB-regulated genes, and the NF-kappaB consensus sequence has more than 60 variants with different binding properties. However, our study suggests that the overall basal expression of A20 in neuronal cells is probably regulated by the constitutive NF-kappaB transcription factor. In contrast, after an acute excitotoxic lesion to the immature rat brain, neuronal A20 immunoreactivity decreased rapidly within 10 hours in the cortical lesion core, when neuronal death is an ongoing process, 38 and decreased neuronal A20 was still observed in secondary lesioned areas at 24 hours post-lesion. Noteworthy, we have previously shown that active NFkB is found in injured neurons located in the lesion core at 10 hours post-lesion, 39 correlating with Figure 4 Lesion volume after overexpression of A20 in the excitotoxically injured immature brain. Two hours after NMDA-induced excitotoxic lesion, animals were injected at the same coordinates with the gene therapy vector NLSCt carrying the control transgene (NLSCt/GFP) or the A20 transgene (NLSCt/A20) (A). Image analysis of coronal sections stained with Nissl staining (A) showed that animals overexpressing A20 presented a significant increase in the percentage of lesioned hemisphere (*P,0.05 in relation to NLSCt/GFP injected animals) when compared to the GFP overexpressing transgene control animals (B). neuronal expression of some NF-kappaB-target genes such as cyclooxygenase-2. 40 However, NF-kappaB activation does not seem to be enough to induce the neuronal expression of A20 under these circumstances, suggesting a complex regulation of A20 expression in damaged neurons. Alternatively, the reported decrease in A20 expression could also reflect an effect at the protein level, such as degradation of A20. Later on, 3 days after the excitotoxic damage, A20 expression was induced in some cells that due to their localization and morphology resemble reactive astrocytes, which were distributed in the lesion borders as has been previously described in this model using astroglial markers. 29, 30, 32 In relation to this, we have previously shown that astrocytes located in the neocortical lesion site in the same postnatal injury model, display activated NF-kappaB from a few hours after the lesion, showing maximum astroglial NF-kappaB at 24 hours post-lesion. 39 Therefore, it is likely that NFkappaB may contribute to the induction of A20 in astrocytes, as we have observed expression of other NF-kappaB-regulated genes like iNOS 40 and Cu/Zn SOD 38 in this cell type. Thus, it is conceivable to think that NF-kappaB regulation of its target gene A20 is cell specific, pointing again to a complex regulation of its expression. Moreover, it should be noted that A20 mRNA levels increase in other neuropathological conditions like 6 days after brain infection by dengue Figure 5 Astroglial reactivity after overexpression of A20 in the excitotoxically injured immature brain. Two hours after the NMDA lesion, animals were injected at the same coordinates with the gene delivery vector NLSCt carrying a control transgene (NLSCt/GFP) or the A20 transgene (NLSCt/A20) (A). There were no significant differences in the densitometrical analysis of GFAP immunoreactivity (B) nor in the percentage of GFAP immunoreactive area within ROI (C) between animals overexpressing GFP or A20.
virus 41 and in total cortex homogenates of cryolesioned brain at 8 hours post-lesion. 17 However, relevant cell types were not identified in these studies.
Effects of A20 overexpression
To our knowledge, very few studies have evaluated the effects of A20 overexpression in CNS cells. We here report that A20 overexpression in cortical cultures induced significant neuronal cell death, in agreement with previous work demonstrating that A20 increases cell vulnerability to reactive oxygen species, triggering necrosis, 14 an effect that was dependent on the A20-mediated NF-kappaB inhibition. This effect could also explain, at least in part, why A20 overexpression 2 hours after the excitotoxic lesion to the immature brain enhanced lesion volume, as oxidative stress plays a critical role in promoting neurodegeneration in this postnatal lesion model. 26 In comparison, the overexpression of the NF-kappaB inhibitor IkappaBm both in vitro and in vivo showed a non-significant similar trend towards an increase in neurodegeneration. The lack of a significant effect of IkappaBm in this context could suggest other functions of A20 not mediated by NF-kappaB, or variable effects induced by different NF-kappaB inhibiting mechanisms. A previous study analyzing the effects of A20 overexpression in vitro and in vivo has described a significant neuroprotective effect of A20 gene transfer when administered 2 days before middle cerebral artery occlusion in adult rats and in hippocampal cultures. 42 This neuroprotective effect was attributed to an A20-mediated inhibition of TNF-induced apoptosis by inhibiting the proteolytic cleavage of caspase-8 and -3, 42 pointing to a clear anti-apoptotic action of A20. Several reasons may account for the differences between the cited study and our results. First, the pre-treatment paradigm used by Yu and colleagues, which could induce NF-kappaB-mediated preconditioning effects, contrasts with our postlesion treatment experimental design. Second, a different neuropathological process due to brain immaturity of CNS 18 occurs after postnatal excitotoxic damage, when activation of caspase-8 dependent pathway is not the main mechanism mediating neuronal cell death. 43 Finally, another reason behind these discrepancies could be attributed to the in vitro and in vivo transfection methods used, and their possible interaction or synergism with the physiological role of A20. However, here we used, on one hand, a previously characterized modular recombinant gene therapy vehicle for in vivo overexpression of A20 and, on the other hand, lipofectamine for the in vitro overexpression. Noticeably, in both cases, the result obtained was an increase in neurodegeneration, pointing against the existence of potential interactions between the transfection method used and the physiological role of A20. An important number of studies have addressed in the last decade the effects of NF-kappaB inhibition in the CNS by using several mechanisms. In general, inhibition of NF-kappaB under physiological conditions in vivo does not seem to induce cell death 44, 45 but causes learning disabilities. 46 Also, several in vitro studies have shown that NF-kappaB inhibition induced cell death in several cultured neuronal cell types 47, 48 including cortical neurons, 37 in agreement with our results on A20 overexpression. Somewhat contradictory results have been reported on the effects of the inhibition of NF-kappaB signalling after acute injuries. NF-kappaB inhibition sensitizes cultured neurons to excitotoxic 49, 50 and amyloid beta peptideinduced cell death 51 . In vivo NF-kappaB inhibition after acute injuries to the adult brain increases, in most cases, neurodegeneration. 46, 49, [52] [53] [54] although other studies demonstrated decreased lesion volume after transient focal ischemia. [55] [56] [57] [58] Taken together, these observations suggest that the level of A20 expression, and thus possibly of NFkappaB activity within neurons should be preserved in a certain physiological range, which could be maintained by an autoregulatory loop including the expression of NF-kappaB inhibiting proteins such as IkappaB family members or deubiquitinating enzymes such as A20 or CYLD. 2 In accordance with these observations, a perturbation of physiological A20 expression could lead to neuropathological changes, which may include cell death. Moreover, as stated above, a NF-kappaB-independent effect of A20 cannot be ruled out. Future experiments are necessary for a better understanding of the functions of A20 in the nervous system both under physiological and pathological conditions. Although A20 was described as a potent anti-inflammatory agent and modulator of inflammation, a parallel action of this molecule inducing neurotoxic effects is here described, precluding the use of A20 as a neuroprotective target gene in non cell-selective gene therapy applications.
Conclusions
Our results showed that A20 was normally expressed in neurons of the immature brain and that after an acute lesion, it was rapidly downregulated in neurons of the lesioned area and also upregulated in reactive astrocyte-like cells. Moreover, the overexpression of A20 in mixed cortical cultures and in vivo after an acute immature brain injury was neurotoxic, and thus cannot be used as an inflammatory modulating transgene for neuroprotective gene therapy applications.
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